{
    "clinical_study": {
        "@rank": "30129", 
        "arm_group": [
            {
                "arm_group_label": "TIVf (18 to \u2264 60 years)", 
                "arm_group_type": "Experimental", 
                "description": "Adult subjects aged 18 to \u2264 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere"
            }, 
            {
                "arm_group_label": "TIVf (\u2265 61 years)", 
                "arm_group_type": "Experimental", 
                "description": "Adult subjects aged \u2265 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere"
            }
        ], 
        "brief_summary": {
            "textblock": "The present study is designed to confirm the safety and immunogenicity of trivalent, surface\n      antigen, inactivated influenza vaccine  in 2 age cohorts: 18 to \u226460 years and \u226561 years and\n      the antibody response to each influenza vaccine antigen, as measured by Single Radial\n      Hemolysis (SRH) or Hemagglutination Inhibition (HI) at approximately 21 days post\n      immunization.\n\n      The vaccine composition will be based on the World Health Organization (WHO) recommended\n      influenza strains for the 2013/2014 Northern Hemisphere vaccine.\n\n      The results of this study are intended to support the use of this vaccine in future\n      influenza seasons if the recommended vaccine composition remains the same, in compliance\n      with the requirements of the current European Union (EU) recommendations for clinical trials\n      related to yearly licensing of influenza vaccines."
        }, 
        "brief_title": "Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "B1", 
                            "description": "Adult subjects aged 18 to \u2264 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                            "title": "TIVf (18 to \u2264 60 Years)"
                        }, 
                        {
                            "@group_id": "B2", 
                            "description": "Adult subjects aged \u2265 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                            "title": "TIVf (\u2265 61 Years)"
                        }, 
                        {
                            "@group_id": "B3", 
                            "description": "Total of all reporting groups", 
                            "title": "Total"
                        }
                    ]
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@value": "61"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@value": "64"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@value": "125"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@spread": "11.2", 
                                                "@value": "39.2"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@spread": "4.7", 
                                                "@value": "68.2"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@spread": "16.9", 
                                                "@value": "54.1"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "29"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "34"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "63"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "32"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "30"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "62"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Immunogenicity was assessed in terms of percentages of subjects in both age groups with SRH areas \u226525mm2 against each of the three vaccine strains, three weeks after receiving one dose of TIVf.\nThe related European (CHMP) criterion  for the assessment of immunogenicity is met if the percentage of subjects achieving  post vaccination SRH areas \u2265 25mm2 is >70% for adults aged 18 to \u226460 years and >60% for subjects aged  \u226561 years.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Adult subjects aged 18 to \u2264 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (18 to \u2264 60 Years)"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Adult subjects aged \u2265 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (\u2265 61 Years)"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "64"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "8", 
                                                            "@upper_limit": "29", 
                                                            "@value": "17"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "24", 
                                                            "@upper_limit": "49", 
                                                            "@value": "36"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Day 1 (H1N1 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "86", 
                                                            "@upper_limit": "99", 
                                                            "@value": "95"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "68", 
                                                            "@upper_limit": "89", 
                                                            "@value": "80"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Day 22 (H1N1 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "11", 
                                                            "@upper_limit": "32", 
                                                            "@value": "20"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "11", 
                                                            "@upper_limit": "32", 
                                                            "@value": "20"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Day 1 (H3N2 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "70", 
                                                            "@upper_limit": "90", 
                                                            "@value": "82"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "73", 
                                                            "@upper_limit": "92", 
                                                            "@value": "84"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Day 22 (H3N2 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "43", 
                                                            "@upper_limit": "69", 
                                                            "@value": "57"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "42", 
                                                            "@upper_limit": "67", 
                                                            "@value": "55"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Day 1 (B strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "82", 
                                                            "@upper_limit": "97", 
                                                            "@value": "92"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "83", 
                                                            "@upper_limit": "97", 
                                                            "@value": "92"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Day 22 (B strain)"
                                            }
                                        ]
                                    }, 
                                    "description": "Immunogenicity was assessed in terms of percentages of subjects in both age groups with SRH areas \u226525mm2 against each of the three vaccine strains, three weeks after receiving one dose of TIVf.\nThe related European (CHMP) criterion  for the assessment of immunogenicity is met if the percentage of subjects achieving  post vaccination SRH areas \u2265 25mm2 is >70% for adults aged 18 to \u226460 years and >60% for subjects aged  \u226561 years.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Percentage of Subjects With Single Radial Hemolysis (SRH) Areas \u226525mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf", 
                                    "units": "Percentages of subjects"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the per-protocol population i.e all subjects who have received study vaccination  and provided immunogenicity data both at baseline and after vaccination;  did not withdraw informed consent and did not have Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) confirmed influenza during the study.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (baseline) and Day 22 (postvaccination)", 
                        "title": "Percentage of Subjects With Single Radial Hemolysis (SRH) Areas \u226525mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Immunogenicity was assessed in terms of percentages of subjects in both age groups achieving seroconversion or significant increase by SRH area against each of the three vaccine strains ,three weeks after receiving one dose of TIVf.\nSeroconversion is defined as percentage of subjects with a pre vaccination SRH area \u22644mm2 achieving a post vaccination SRH area \u226525 mm2. Significant increase is defined as percentage of subjects with a pre vaccination SRH area >4mm2 achieving at least 50% increase in post vaccination SRH area.\nThe related European (CHMP)  criterion for the assessment of immunogenicity is met if the percentage of subjects achieving  post vaccination SRH areas \u2265 25mm2 is  >40% for adults aged 18 to \u226460 years and >30% for subjects aged  \u226561 years.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Adult subjects aged 18 to \u2264 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (18 to \u2264 60 Years)"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Adult subjects aged \u2265 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (\u2265 61 Years)"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "64"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "73", 
                                                            "@upper_limit": "93", 
                                                            "@value": "85"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "45", 
                                                            "@upper_limit": "70", 
                                                            "@value": "58"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "H1N1 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "77", 
                                                            "@upper_limit": "95", 
                                                            "@value": "88"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "61", 
                                                            "@upper_limit": "84", 
                                                            "@value": "73"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "H3N2 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "55", 
                                                            "@upper_limit": "80", 
                                                            "@value": "68"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "54", 
                                                            "@upper_limit": "78", 
                                                            "@value": "67"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "B strain"
                                            }
                                        ]
                                    }, 
                                    "description": "Immunogenicity was assessed in terms of percentages of subjects in both age groups achieving seroconversion or significant increase by SRH area against each of the three vaccine strains ,three weeks after receiving one dose of TIVf.\nSeroconversion is defined as percentage of subjects with a pre vaccination SRH area \u22644mm2 achieving a post vaccination SRH area \u226525 mm2. Significant increase is defined as percentage of subjects with a pre vaccination SRH area >4mm2 achieving at least 50% increase in post vaccination SRH area.\nThe related European (CHMP)  criterion for the assessment of immunogenicity is met if the percentage of subjects achieving  post vaccination SRH areas \u2265 25mm2 is  >40% for adults aged 18 to \u226460 years and >30% for subjects aged  \u226561 years.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Percentages of Subjects With Seroconversion or Significant Increase in SRH Area, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf", 
                                    "units": "Percentages of subjects"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the per-protocol population", 
                        "safety_issue": "No", 
                        "time_frame": "Day 22 (postvaccination)  /Day 1 (Baseline)", 
                        "title": "Percentages of Subjects With Seroconversion or Significant Increase in SRH Area, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The antibody responses were evaluated in terms of GMRs of post vaccination GMAs to pre vaccination GMAs against each of the three vaccine strains, three weeks after receiving one dose of TIVf.\nThe related European Committee for Human Medicinal Products (CHMP) criterion for the assessment of immunogenicity is met if the GMR day 22/day 1 is >2.5 for adults aged 18 to \u226460 years and > 2.0  for subjects aged \u226561 years.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Adult subjects aged 18 to \u2264 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (18 to \u2264 60 Years)"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Adult subjects aged \u2265 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (\u2265 61 Years)"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "64"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "5.83", 
                                                            "@upper_limit": "9.95", 
                                                            "@value": "7.62"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "2.65", 
                                                            "@upper_limit": "4.41", 
                                                            "@value": "3.42"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "H1N1 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "2.98", 
                                                            "@upper_limit": "4.5", 
                                                            "@value": "3.66"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "2.49", 
                                                            "@upper_limit": "3.74", 
                                                            "@value": "3.05"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "H3N2 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "2.09", 
                                                            "@upper_limit": "3.27", 
                                                            "@value": "2.62"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "1.92", 
                                                            "@upper_limit": "2.83", 
                                                            "@value": "2.33"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "B strain"
                                            }
                                        ]
                                    }, 
                                    "description": "The antibody responses were evaluated in terms of GMRs of post vaccination GMAs to pre vaccination GMAs against each of the three vaccine strains, three weeks after receiving one dose of TIVf.\nThe related European Committee for Human Medicinal Products (CHMP) criterion for the assessment of immunogenicity is met if the GMR day 22/day 1 is >2.5 for adults aged 18 to \u226460 years and > 2.0  for subjects aged \u226561 years.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Geometric Mean", 
                                    "title": "Geometric Mean Ratio (GMR) of Post Vaccination Versus Pre Vaccination Geometric Mean Areas (GMAs), After One Dose of TIVf", 
                                    "units": "Ratio"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the per-protocol population", 
                        "safety_issue": "No", 
                        "time_frame": "Day 22 (postvaccination)/ Day 1 (baseline)", 
                        "title": "Geometric Mean Ratio (GMR) of Post Vaccination Versus Pre Vaccination Geometric Mean Areas (GMAs), After One Dose of TIVf", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Immunogenicity was assessed in terms of percentages of subjects in both age groups with HI titers \u226540, against each of the three vaccine strains, three weeks after receiving one dose of TIVf.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the percentage of subjects achieving HI titers \u2265 40 is >70% for adults aged 18 to \u226460 years and >60% for subjects aged  \u226561 years.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Adult subjects aged 18 to \u2264 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (18 to \u2264 60 Years)"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Adult subjects aged \u2265 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (\u2265 61 Years)"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "64"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "37", 
                                                            "@upper_limit": "63", 
                                                            "@value": "50"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "43", 
                                                            "@upper_limit": "69", 
                                                            "@value": "56"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Day 1 (H1N1 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "94", 
                                                            "@upper_limit": "100", 
                                                            "@value": "100"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "94", 
                                                            "@upper_limit": "100", 
                                                            "@value": "100"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Day 22 (H1N1 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "48", 
                                                            "@upper_limit": "74", 
                                                            "@value": "62"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "61", 
                                                            "@upper_limit": "84", 
                                                            "@value": "73"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Day 1 (H3N2strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "91", 
                                                            "@upper_limit": "100", 
                                                            "@value": "98"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "94", 
                                                            "@upper_limit": "100", 
                                                            "@value": "100"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Day 22 (H3N2 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "32", 
                                                            "@upper_limit": "58", 
                                                            "@value": "45"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "33", 
                                                            "@upper_limit": "58", 
                                                            "@value": "45"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Day 1 (B strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "84", 
                                                            "@upper_limit": "98", 
                                                            "@value": "93"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "68", 
                                                            "@upper_limit": "89", 
                                                            "@value": "80"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Day 22 (B strain)"
                                            }
                                        ]
                                    }, 
                                    "description": "Immunogenicity was assessed in terms of percentages of subjects in both age groups with HI titers \u226540, against each of the three vaccine strains, three weeks after receiving one dose of TIVf.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the percentage of subjects achieving HI titers \u2265 40 is >70% for adults aged 18 to \u226460 years and >60% for subjects aged  \u226561 years.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Percentages of Subjects With Haemagglutination Inhibition (HI) Titers \u226540, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf", 
                                    "units": "Percentages of subjects"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the per-protocol population", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (baseline) and Day 22 (postvaccination)", 
                        "title": "Percentages of Subjects With Haemagglutination Inhibition (HI) Titers \u226540, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Immunogenicity was assessed in terms of percentages of subjects in both age groups achieving seroconversion or significant increase in HI antibody titers after receiving one dose of TIVf.\nSeroconversion is defined as percentage of subjects with a pre vaccination HI titer <10 to a post vaccination titer \u226540. Significant increase is defined as percentage of subjects with a pre vaccination HI titer \u226510 to at least a 4-fold increase in post vaccination HI antibody titers.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if>40 % for adults aged 18 to \u226460 years and>30% for subjects aged \u226561 years achieve seroconversion or significant increase in post vaccination HI titers.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Adult subjects aged 18 to \u2264 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (18 to \u2264 60 Years)"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Adult subjects aged \u2265 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (\u2265 61 Years)"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "64"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "66", 
                                                            "@upper_limit": "88", 
                                                            "@value": "78"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "58", 
                                                            "@upper_limit": "81", 
                                                            "@value": "70"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "H1N1 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "70", 
                                                            "@upper_limit": "90", 
                                                            "@value": "82"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "43", 
                                                            "@upper_limit": "69", 
                                                            "@value": "56"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "H3N2 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "40", 
                                                            "@upper_limit": "66", 
                                                            "@value": "53"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "16", 
                                                            "@upper_limit": "39", 
                                                            "@value": "27"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "B strain"
                                            }
                                        ]
                                    }, 
                                    "description": "Immunogenicity was assessed in terms of percentages of subjects in both age groups achieving seroconversion or significant increase in HI antibody titers after receiving one dose of TIVf.\nSeroconversion is defined as percentage of subjects with a pre vaccination HI titer <10 to a post vaccination titer \u226540. Significant increase is defined as percentage of subjects with a pre vaccination HI titer \u226510 to at least a 4-fold increase in post vaccination HI antibody titers.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if>40 % for adults aged 18 to \u226460 years and>30% for subjects aged \u226561 years achieve seroconversion or significant increase in post vaccination HI titers.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Percentages of Subjects With Seroconversion or Significant Increase in HI Antibody Titers After Receiving One Dose of TIVf", 
                                    "units": "percentages of subjects"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the per-protocol population", 
                        "safety_issue": "No", 
                        "time_frame": "Day 22 (postvaccination)/ Day 1 (baseline)", 
                        "title": "Percentages of Subjects With Seroconversion or Significant Increase in HI Antibody Titers After Receiving One Dose of TIVf", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The antibody responses following one dose of  TIVf  were evaluated in terms of GMRs of post vaccination against pre vaccination  geometric mean HI titers against each of the three vaccine strains, three weeks after receiving one dose of TIVf.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the GMR day 22/day 1 is >2.5 for adults aged 18 to \u226460 years and > 2.0 for subjects aged  \u226561 years.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Adult subjects aged 18 to \u2264 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (18 to \u2264 60 Years)"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Adult subjects aged \u2265 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (\u2265 61 Years)"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "64"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "16", 
                                                            "@upper_limit": "46", 
                                                            "@value": "27"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "7.36", 
                                                            "@upper_limit": "18", 
                                                            "@value": "11"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "H1N1 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "7.31", 
                                                            "@upper_limit": "14", 
                                                            "@value": "10"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "4.73", 
                                                            "@upper_limit": "11", 
                                                            "@value": "7.34"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "H3N2 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "3.67", 
                                                            "@upper_limit": "7.77", 
                                                            "@value": "5.34"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "1.94", 
                                                            "@upper_limit": "3.33", 
                                                            "@value": "2.54"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "B strain"
                                            }
                                        ]
                                    }, 
                                    "description": "The antibody responses following one dose of  TIVf  were evaluated in terms of GMRs of post vaccination against pre vaccination  geometric mean HI titers against each of the three vaccine strains, three weeks after receiving one dose of TIVf.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the GMR day 22/day 1 is >2.5 for adults aged 18 to \u226460 years and > 2.0 for subjects aged  \u226561 years.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Geometric Mean", 
                                    "title": "Geometric Mean Ratio of Post Vaccination Versus Pre Vaccination HI Antibody Titers, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf", 
                                    "units": "Ratio"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the per-protocol population", 
                        "safety_issue": "No", 
                        "time_frame": "Day 22/ Day 1", 
                        "title": "Geometric Mean Ratio of Post Vaccination Versus Pre Vaccination HI Antibody Titers, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The number of adult and elderly subjects reporting solicited local and systemic AEs and other solicited AEs after receiving one dose of TIVf are reported.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Adult subjects aged 18 to \u2264 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (18 to \u2264 60 Years)"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Adult subjects aged \u2265 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (\u2265 61 Years)"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "61"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "64"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "31"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "18"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Injection site  pain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "4"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "1"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Injection site  ecchymosis"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "2"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "10"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Injection site erythema"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "7"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "8"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Injection site induration"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "3"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Chills/shivering"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "8"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "1"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Malaise"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "2"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "2"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Myalgia"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "5"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "1"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Arthralgia"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "14"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "5"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Headache"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "14"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "6"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Fatigue"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Fever (\u226538\u00b0C)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Prophylactic use of analgesic/antipyretics N=61,62"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "3"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Therapeutic use of analgesics/antipyretics N=61,62"
                                            }
                                        ]
                                    }, 
                                    "description": "The number of adult and elderly subjects reporting solicited local and systemic AEs and other solicited AEs after receiving one dose of TIVf are reported.", 
                                    "param": "Number", 
                                    "title": "Number of Subjects Reporting Solicited Adverse Events (AEs) After Receiving One Dose of TIVf", 
                                    "units": "Subjects"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the safety set population i.e all subjects who have post-vaccination AE or reactogenicity records", 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1 through Day 4 postvaccination", 
                        "title": "Number of Subjects Reporting Solicited Adverse Events (AEs) After Receiving One Dose of TIVf", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The number of subjects in both age groups reporting any unsolicited AEs (between Day 1 to 4), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal (throughout the study period), after receiving one dose of TIVf is reported.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Adult subjects aged 18 to \u2264 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (18 to \u2264 60 Years)"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Adult subjects aged \u2265 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                                    "title": "TIVf (\u2265 61 Years)"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "61"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "64"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "3"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "3"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Any AE"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "1"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "3"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Possibly/Probably related AE"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Any SAE"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Possibly/Probably related SAE"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "1"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Medically attended AE"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "AE leading to premature withdrawal"
                                            }
                                        ]
                                    }, 
                                    "description": "The number of subjects in both age groups reporting any unsolicited AEs (between Day 1 to 4), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal (throughout the study period), after receiving one dose of TIVf is reported.", 
                                    "param": "Number", 
                                    "title": "Number of Subjects Reporting Unsolicited Adverse Events After Receiving One Dose of TIVf", 
                                    "units": "Subjects"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the safety set population", 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1(baseline) through Day 22 postvaccination", 
                        "title": "Number of Subjects Reporting Unsolicited Adverse Events After Receiving One Dose of TIVf", 
                        "type": "Primary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "P1", 
                            "description": "Adult subjects aged 18 to \u2264 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                            "title": "TIVf (18 to \u2264 60 Years)"
                        }, 
                        {
                            "@group_id": "P2", 
                            "description": "Adult subjects aged \u2265 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                            "title": "TIVf (\u2265 61 Years)"
                        }
                    ]
                }, 
                "period_list": {
                    "period": {
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "61", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "64", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "61", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "64", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "0", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "recruitment_details": "Subjects were enrolled from one center in Germany."
            }, 
            "point_of_contact": {
                "email": "RegistryContactVaccinesUS@novartis.com", 
                "name_or_title": "Posting Director", 
                "organization": "Novartis Vaccines and Diagnostics"
            }, 
            "reported_events": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "E1", 
                            "description": "Adult subjects aged 18 to \u2264 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                            "title": "TIVf (18 to \u2264 60 Years)"
                        }, 
                        {
                            "@group_id": "E2", 
                            "description": "Adult subjects aged \u2265 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere", 
                            "title": "TIVf (\u2265 61 Years)"
                        }
                    ]
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "41", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "24", 
                                                "@subjects_at_risk": "64"
                                            }
                                        ], 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "14", 
                                                    "@subjects_at_risk": "61"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "6", 
                                                    "@subjects_at_risk": "64"
                                                }
                                            ], 
                                            "sub_title": "Fatigue"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "33", 
                                                    "@subjects_at_risk": "61"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "19", 
                                                    "@subjects_at_risk": "64"
                                                }
                                            ], 
                                            "sub_title": "Injection site pain"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "9", 
                                                    "@subjects_at_risk": "61"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "64"
                                                }
                                            ], 
                                            "sub_title": "Malaise"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "5", 
                                                    "@subjects_at_risk": "61"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "64"
                                                }
                                            ], 
                                            "sub_title": "Arthralgia"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "14", 
                                                    "@subjects_at_risk": "61"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "5", 
                                                    "@subjects_at_risk": "64"
                                                }
                                            ], 
                                            "sub_title": "Headache"
                                        }
                                    ]
                                }, 
                                "title": "Musculoskeletal and connective tissue disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "MedDRA (Unspecified)", 
                    "frequency_threshold": "5"
                }, 
                "time_frame": "All solicited AEs and unsolicited AEs were collected from Day1 to Day 4; all unsolicited SAEs, medically attended AEs, AEs leading to withdrawal from the study were collected from Day1 to Day 22"
            }
        }, 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Human Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female volunteer aged 18 years or older, mentally competent, who gave written\n             informed consent prior to study entry;\n\n          -  Able to comply with all the study requirements; and\n\n          -  In good health as determined by the outcome of medical history, physical examination,\n             and clinical judgment of the investigator\n\n        Exclusion Criteria:\n\n          -  Any behavioral or cognitive impairment or psychiatric disease that, in the opinion of\n             the investigator, may have interfered with the subject's ability to participate in\n             the study;\n\n          -  any serious chronic or acute disease (in the judgment of the investigator) including,\n             but not limited to\n\n               -  medically significant cancer (except for benign or localized skin cancer, cancer\n                  in remission for \u226510 years, or localized prostate cancer that has been\n                  clinically stable for >2 years without treatment)\n\n               -  medically significant advanced congestive heart failure (ie, New York Heart\n                  Association (NYHA) class III and IV)\n\n               -  chronic obstructive pulmonary disease (ie, Global initiative for chronic\n                  Obstructive Lung Disease (GOLD) stage III and IV)\n\n               -  autoimmune disease (including rheumatoid arthritis and excepting Hashimoto's\n                  thyroiditis that had been clinically stable for \u22655 years)\n\n               -  diabetes mellitus type I\n\n               -  poorly controlled diabetes mellitus type II\n\n               -  advanced arteriosclerotic disease\n\n               -  history of underlying medical condition such as major congenital abnormalities\n                  requiring surgery, chronic treatment, or associated with developmental delay\n                  (Down's syndrome), acute or progressive hepatic disease\n\n               -  acute or progressive renal disease\n\n               -  severe neurological (especially Guillain-Barr\u00e9 syndrome) or psychiatric disorder\n\n               -  severe asthma\n\n          -  history of any anaphylactic reaction and/or serious allergic reaction to any\n             component of the study vaccine;\n\n          -  a known or suspected (or had a high risk of developing) impairment/alteration of\n             immune function (excluding those normally associated with advanced age) resulting,\n             for example, from:\n\n               -  receipt of immunosuppressive therapy (any parenteral or oral corticosteroid or\n                  cancer chemotherapy/radiotherapy) within the past 60 days and for the full\n                  length of the study,\n\n               -  receipt of immunostimulants within the past 6 months,\n\n               -  receipt of parenteral immunoglobulin preparation, blood products, and/or plasma\n                  derivates within the past 3 months and for the full length of the study, or\n\n               -  suspected or known human immunodeficiency virus (HIV) infection or HIV-related\n                  disease\n\n          -  Had known or suspected drug or alcohol abuse within the past 2 years;\n\n          -  Had bleeding diathesis or conditions associated with prolonged bleeding time that, in\n             the investigator's opinion, would interfere with the safety of the subject;\n\n          -  was not able to comprehend and to follow all required study procedures for the whole\n             period of the study;\n\n          -  Had a history or any illness that, in the opinion of the investigator, would pose\n             additional risk to the subjects because of participation in the study;\n\n          -  Had the following within the past 6 months:\n\n               -  had any laboratory-confirmed seasonal or pandemic influenza disease\n\n               -  received any seasonal or pandemic influenza vaccine\n\n          -  Had received any other vaccine within 4 weeks prior to enrollment in this study or\n             who were planning to receive any vaccine during the study;\n\n          -  Had acute or chronic infections requiring antiviral therapy within the last 7 days;\n\n          -  Had experienced fever (ie, body temperature [preferably oral] \u226538.0\u00b0C) within the\n             last 3 days of intended study vaccination;\n\n          -  Had been participating in any clinical trial with another investigational product 4\n             weeks prior to first study visit or intends to participate in another clinical study\n             at any time during the conduct of this study;\n\n          -  was part of study personnel or has close family members conducting this study;\n\n          -  Had a body mass index (BMI) >35 kg/m2 (BMI is calculated by dividing the subject's\n             weight in kilograms by the subject's height in meters multiplied by the subject's\n             height in meters);\n\n          -  was pregnant (confirmed by positive urine pregnancy test) or nursing (breast feeding)\n             or was a female of childbearing potential who refused to use an acceptable method of\n             birth control for the whole duration of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "firstreceived_results_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885117", 
            "org_study_id": "V78_11S", 
            "secondary_id": "2013-000601-23"
        }, 
        "intervention": {
            "arm_group_label": [
                "TIVf (18 to \u2264 60 years)", 
                "TIVf (\u2265 61 years)"
            ], 
            "description": "Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)", 
            "intervention_name": "TIVf", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Influenza,", 
            "Adults,", 
            "Elderly,", 
            "Immunology,", 
            "Safety"
        ], 
        "lastchanged_date": "February 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hamburg", 
                    "country": "Germany", 
                    "zip": "20359"
                }, 
                "name": "University Medical Center Hamburg-Eppendorf"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Open Label, Single Arm, Multi Center Study to Evaluate Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus (Fluvirin\u00ae) in Healthy Adults", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Immunogenicity was assessed in terms of percentages of subjects in both age groups with SRH areas \u226525mm2 against each of the three vaccine strains, three weeks after receiving one dose of TIVf.\nThe related European (CHMP) criterion  for the assessment of immunogenicity is met if the percentage of subjects achieving  post vaccination SRH areas \u2265 25mm2 is >70% for adults aged 18 to \u226460 years and >60% for subjects aged  \u226561 years.", 
                "measure": "Percentage of Subjects With Single Radial Hemolysis (SRH) Areas \u226525mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (baseline) and Day 22 (postvaccination)"
            }, 
            {
                "description": "Immunogenicity was assessed in terms of percentages of subjects in both age groups achieving seroconversion or significant increase by SRH area against each of the three vaccine strains ,three weeks after receiving one dose of TIVf.\nSeroconversion is defined as percentage of subjects with a pre vaccination SRH area \u22644mm2 achieving a post vaccination SRH area \u226525 mm2. Significant increase is defined as percentage of subjects with a pre vaccination SRH area >4mm2 achieving at least 50% increase in post vaccination SRH area.\nThe related European (CHMP)  criterion for the assessment of immunogenicity is met if the percentage of subjects achieving  post vaccination SRH areas \u2265 25mm2 is  >40% for adults aged 18 to \u226460 years and >30% for subjects aged  \u226561 years.", 
                "measure": "Percentages of Subjects With Seroconversion or Significant Increase in SRH Area, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf", 
                "safety_issue": "No", 
                "time_frame": "Day 22 (postvaccination)  /Day 1 (Baseline)"
            }, 
            {
                "description": "The antibody responses were evaluated in terms of GMRs of post vaccination GMAs to pre vaccination GMAs against each of the three vaccine strains, three weeks after receiving one dose of TIVf.\nThe related European Committee for Human Medicinal Products (CHMP) criterion for the assessment of immunogenicity is met if the GMR day 22/day 1 is >2.5 for adults aged 18 to \u226460 years and > 2.0  for subjects aged \u226561 years.", 
                "measure": "Geometric Mean Ratio (GMR) of Post Vaccination Versus Pre Vaccination Geometric Mean Areas (GMAs), After One Dose of TIVf", 
                "safety_issue": "No", 
                "time_frame": "Day 22 (postvaccination)/ Day 1 (baseline)"
            }, 
            {
                "description": "Immunogenicity was assessed in terms of percentages of subjects in both age groups with HI titers \u226540, against each of the three vaccine strains, three weeks after receiving one dose of TIVf.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the percentage of subjects achieving HI titers \u2265 40 is >70% for adults aged 18 to \u226460 years and >60% for subjects aged  \u226561 years.", 
                "measure": "Percentages of Subjects With Haemagglutination Inhibition (HI) Titers \u226540, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (baseline) and Day 22 (postvaccination)"
            }, 
            {
                "description": "Immunogenicity was assessed in terms of percentages of subjects in both age groups achieving seroconversion or significant increase in HI antibody titers after receiving one dose of TIVf.\nSeroconversion is defined as percentage of subjects with a pre vaccination HI titer <10 to a post vaccination titer \u226540. Significant increase is defined as percentage of subjects with a pre vaccination HI titer \u226510 to at least a 4-fold increase in post vaccination HI antibody titers.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if>40 % for adults aged 18 to \u226460 years and>30% for subjects aged \u226561 years achieve seroconversion or significant increase in post vaccination HI titers.", 
                "measure": "Percentages of Subjects With Seroconversion or Significant Increase in HI Antibody Titers After Receiving One Dose of TIVf", 
                "safety_issue": "No", 
                "time_frame": "Day 22 (postvaccination)/ Day 1 (baseline)"
            }, 
            {
                "description": "The antibody responses following one dose of  TIVf  were evaluated in terms of GMRs of post vaccination against pre vaccination  geometric mean HI titers against each of the three vaccine strains, three weeks after receiving one dose of TIVf.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the GMR day 22/day 1 is >2.5 for adults aged 18 to \u226460 years and > 2.0 for subjects aged  \u226561 years.", 
                "measure": "Geometric Mean Ratio of Post Vaccination Versus Pre Vaccination HI Antibody Titers, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf", 
                "safety_issue": "No", 
                "time_frame": "Day 22/ Day 1"
            }, 
            {
                "description": "The number of adult and elderly subjects reporting solicited local and systemic AEs and other solicited AEs after receiving one dose of TIVf are reported.", 
                "measure": "Number of Subjects Reporting Solicited Adverse Events (AEs) After Receiving One Dose of TIVf", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 through Day 4 postvaccination"
            }, 
            {
                "description": "The number of subjects in both age groups reporting any unsolicited AEs (between Day 1 to 4), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal (throughout the study period), after receiving one dose of TIVf is reported.", 
                "measure": "Number of Subjects Reporting Unsolicited Adverse Events After Receiving One Dose of TIVf", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1(baseline) through Day 22 postvaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885117"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}